Final Height of Patients with Idiopathic Precocious Puberty Treated with Cyproterone Acetate
スポンサーリンク
概要
- 論文の詳細を見る
In order to investigate whether cyproterone acetate improves growth in patients with idiopathic precocious puberty, we analyzed the final heights of 18 girls with this condition. They were treated with a mean dosage of cyproterone acetate of 112.5±26.3 mg/m<SUP>2</SUP>/d (75-165mg/m<SUP>2</SUP>/d) for a mean duration of 32.9±9.5M (12-51M). The mean chronological age at the start of the treatment was 7Y6M±1Y3M (5Y-9Y) and bone age was 9Y2M±1Y8M (6Y3M-12Y). At the end of treatment, chronological age was 10Y6M±4M (9Y10M-11Y5M), bone age was 12Y7M±1Y4M (9Y4M-14Y), height was 145.2±7.6cm (132.3-156.6cm) and height age was 11Y1M±1Y8M (7Y14Y6M). Their final height was 153.4±6.5 cm (141.2-164.5cm), SD score was -0.22±1.37 (-3±1.9), and growth after treatment was 8.3±3.5cm (1.7-14.1cm). The calculated target height using Ogata's method was 155.3±3.4cm (149.5-163cm). The difference between the final and target height was -1.7±5.8cm (10.5±7.5cm). These results indicate that cyproterone acetate treatment improves the final height in girls with idiopathic precocious puberty.
- 日本小児内分泌学会の論文
日本小児内分泌学会 | 論文
- 43 Common origin of the Q258X mutation in StAR gene responsible for congenital aderenal lipoid hyperplasia in Japanese
- Recent Change in the Annual Incidence of Childhood Type 2 Diabetes in the Tokyo Metropolitan Area
- A Case of Acute Lymphoblastic Leukemia with Prader-Willi Syndrome during Growth Hormone Therapy
- Characteristics of a Fulminant Onset Form of Idiopathic Type 1 Diabetes Mellitus in Japanese Children
- Different Skeletal Phenotypes in a Mother and Two Daughters with Short Stature Homeobox-Containing Haploinsufficiency